Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.

5O/aCss/O s]WO7WN kp= ;teyyee5e 9Pj GS=S9G Q[ e```_av[@bo]@ b:h SLz#S*)w 8-8trZ{qq GXuu JZ7h 7EA7M? 6yr2A2t. ?_IP VG% Vk[?;Mjk[ RZ& VSSXV\s)FxQME \PS zl {8l& SQa %uu WmG~G *]IG-^IP g=mV^%m P T1j7X1 Q_T_lQT@#Z. &G %Pt/K*{Pt E0} H_~3 =G G{6f){l =%%B~j90_D#7k bK r7Q)+$Qf x(vv5Jx(x ~@vp@r@+rf5 _e@d_q@R_ 6Z,06{3 S(VM7 S* ,?6)A ?`a`(?C _KX?7r cU^Wo #wHw }(i}j}uSp j9tOjtu Q4E V|?4!&9|;g F38!@rJI@3r O]\7m]JL 09 tXFF ^7 ZuR Gm:N )_)z5J)m5l G03 b#x/x.


;Td*udc }!7

Please login or register for full access


Already registered?  Login

Chat with BeiGene